Navigation Links
Medical Futures partners with Norgine for MOVIPREP(R) in Canada
Date:12/5/2008

RICHMOND HILL, ON, Dec. 5 /PRNewswire/ - Norgine, the leading European specialty pharmaceutical company, has today announced that it has granted Medical Futures the exclusive rights to market MOVIPREP(R) in Canada.

MOVIPREP is a novel patent-protected product developed by Norgine for bowel cleansing prior to colonoscopy and other situations where a clean bowel is required. The product is marketed by Norgine in Europe and in the USA by its partner Salix Pharmaceuticals.

In return for the rights granted to it, Medical Futures will make an upfront payment to Norgine as well as further milestones and royalty payments on sales. The precise details of the deal have not been disclosed.

"This agreement with Norgine underlines Medical Futures' commitment to the prevention and treatment of gastrointestinal diseases," said Par Nijhawan, Medical Futures, Chief Medical Officer.

Commenting on the agreement Peter Stein, Norgine's CEO, said "We are delighted to be working with Medical Futures in Canada. They are a relatively young company but have established a strong presence in the gastroenterology market."

Medical Futures Inc. is a privately held pharmaceutical company specializing in the gastrointestinal therapeutic area. Medical Futures is dedicated to improving quality of life and provides safe, effective and affordable medicines to Canadians. These medicines include:

FLORASTOR(TM): The world's number one probiotic treatment for diarrhea. Florastor(TM) has proven efficacy in the prevention and treatment of all types of diarrhea: Pediatric Diarrhea, Antibiotic Associated Diarrhea, Clostridium Difficile and Travellers' Diarrhea.

IBEROGAST(TM): The leading product for Irritable Bowel Syndrome and Functional Dyspepsia for over forty years in Europe and is now available in North America.

PROFERRIN(TM): A unique heme iron supplement that has higher absorption and lower side effects.

PEGALAX(TM): osmotic laxative with electrolytes for the treatment of chronic constipation.

SANVAR(R): somatostatin analogue for the treatment of esophageal variceal bleeding.

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all the major European markets. In 2007 Norgine's sales were (euro)220 million, the 21st consecutive year of double-digit growth. The company employs over 1,000 people of whom around 400 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL(R) for the treatment of chronic constipation and faecal impaction, MOVIPREP(R) a new generation bowel cleansing preparation, KLEAN-PREP(R) for bowel preparation prior to colonoscopy, and ORAMORPH(R) for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development. In addition to its site at Hengoed, Norgine also has a manufacturing site at Dreux in France.

    Norgine's website is www.norgine.com
    Paul Pay, Vice-President, Corporate & Business Development, Norgine
    Tel: +44 (0)1895 453710
    Email: ppay@norgine.com


'/>"/>
SOURCE Medical Futures Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: